Kiniksa Pharmaceuticals International (KNSA) Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International's Revenue history runs 6 years deep, the most recent figure standing at $214.3 million for Q1 2026.

• Quarterly Revenue rose 55.51% year-over-year to $214.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $754.0 million (up 56.71% YoY) and the FY2025 annual result came in at $677.6 million, up 60.09% from the prior year.
• Revenue was $214.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $202.1 million in the prior quarter.
• Across five years, Revenue topped out at $214.3 million in Q1 2026 and bottomed at -$148.3 million in Q4 2022.
• A 5-year average of $93.8 million and a median of $99.1 million in 2022 frame the typical range for Revenue.
• Peak annual rise in Revenue reached 719.64% in 2022, while the deepest fall reached 891.12% in 2022.
• Kiniksa Pharmaceuticals International's Revenue stood at -$148.3 million in 2022, then jumped by 156.24% to $83.4 million in 2023, then soared by 46.93% to $122.5 million in 2024, then jumped by 64.95% to $202.1 million in 2025, then grew by 6.01% to $214.3 million in 2026.
• Business Quant data shows KNSA's Revenue at $214.3 million in Q1 2026, $202.1 million in Q4 2025, and $180.9 million in Q3 2025.